Early observations and pilot data that first suggested a new direction
Giant cell arteritis (GCA) management relied exclusively on high-dose glucocorticoids for over 50 years, with no proven steroid-sparing agent. While effective at controlling disease, prolonged glucocorticoid use caused substantial morbidity: diabetes, osteoporosis, infections, and cataracts affected the majority of GCA patients, who are typically elderly. Relapse rates during steroid tapering ranged from 40-80%, trapping patients in cycles of high-dose steroids. The unmet need for a steroid-sparing therapy was one of the most pressing in rheumatology.
Landmark RCTs and pivotal trials that established the evidence base
The GiACTA trial was transformative. Among 251 patients with GCA, tocilizumab (weekly or every-other-week) combined with a 26-week prednisone taper achieved sustained glucocorticoid-free remission at 52 weeks in 56% (weekly) and 53% (every-other-week), compared with 14% and 18% for placebo with 26-week and 52-week tapers, respectively (p<0.001 for both comparisons). The cumulative prednisone dose was approximately half in the tocilizumab groups. Tocilizumab became the first non-glucocorticoid therapy FDA-approved for GCA.
Follow-up studies, subgroup analyses, and real-world validation
Long-term extension data from GiACTA showed that tocilizumab maintained its benefit, though some patients relapsed after discontinuation. Post-marketing experience confirmed the steroid-sparing effect in real-world practice but highlighted that tocilizumab suppresses CRP, making inflammatory marker monitoring unreliable during treatment. Imaging with PET-CT or MR angiography became important for monitoring disease activity independent of biochemical markers. The sarilumab GCA trial (SARISTRA) provided additional data supporting IL-6 receptor blockade in GCA.
Integration into clinical practice guidelines and recommendations
ACR/EULAR guidelines recommend tocilizumab as adjunctive therapy with glucocorticoids for all patients with GCA, particularly those at high risk of glucocorticoid toxicity (diabetes, osteoporosis, elderly). The recommended regimen is tocilizumab 162 mg subcutaneously weekly with a rapid prednisone taper over 26 weeks. Guidelines note that CRP and ESR are unreliable markers during tocilizumab therapy.
ACR/VF
Tocilizumab recommended as adjunctive steroid-sparing therapy in GCA; rapid prednisone taper over 26 weeks
EULAR
Tocilizumab recommended for GCA, particularly patients at high risk of GC-related adverse events; CRP unreliable for monitoring during IL-6R blockade
Now
Current standard of care and ongoing research directions
Tocilizumab has transformed GCA management from prolonged glucocorticoid monotherapy to an IL-6R blockade-based steroid-sparing strategy. The key remaining challenges are determining optimal treatment duration (when to stop tocilizumab), managing relapses after discontinuation, and monitoring disease activity when inflammatory markers are suppressed. Emerging therapies including abatacept, secukinumab, and mavrilimumab are under investigation for patients who relapse or cannot tolerate tocilizumab.
How effective is tocilizumab for giant cell arteritis?+
In the GiACTA trial (251 patients), tocilizumab achieved sustained glucocorticoid-free remission in 56% (weekly dosing) and 53% (every-other-week dosing) at 52 weeks, compared with 14-18% with prednisone taper alone. The cumulative prednisone dose was approximately halved. Tocilizumab is the first non-glucocorticoid therapy proven effective for GCA.
Can CRP and ESR be used to monitor GCA during tocilizumab treatment?+
No. Tocilizumab suppresses IL-6 signaling, which drives CRP production, making CRP and ESR unreliable markers of disease activity during treatment. Clinical assessment and imaging (PET-CT, MR angiography) are necessary for monitoring. This is a key consideration highlighted in current EULAR guidelines.
